Why glioblastoma keeps beating treatment: Hidden signaling axis could open new drug path
Glioblastoma progression is driven by an OSMR–CLIC1 signaling axis that integrates microenvironmental cues, sustains brain tumor stem cells, and enhances metabolic stress resistance.
Recent research, published in *Signal Transduction and Targeted Therapy*, identifies a novel OSMR–CLIC1 signaling axis that drives glioblastoma growth and confers resistance to therapy. The study demonstrates that OSMR interacts with chloride intracellular channel 1 (CLIC1), with both proteins supporting brain tumor stem cell maintenance and metabolic adaptation. Genetic deletion or antibody-mediated blockade of membrane CLIC1 disrupts this axis, impairs downstream signaling, and slows tumor progression in preclinical models, highlighting a potential therapeutic vulnerability for glioblastoma.
Targeting the OSMR–CLIC1 axis could open a new therapeutic avenue for glioblastoma, a malignancy with limited effective treatments and poor survival rates.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.